5-LOXIN has been shown in clinical trials to improve joint comfort in as little as 7 days.
Proven efficacy at only 100mg/day.
5-LOXIN is supported by 13 preclinical and 2 human clinical trials.
Both 100mg and 250mg doses improves joint comfort and mobility |
|
Studies show improvement within 7 days |
|
Standardized to 30% AKBA |
|
Thirteen preclinical and two human clinical studies |
|
Significant benefits in WOMAC, VAS and LFI testing |
|
Impacts biological markers associated with joint and general health IL-6 |
|
Supported by extensive safety data |
VEGAN
GLUTEN-FREE
NON-GMO
HALAL
KOSHER
5-LOXIN is a patented, clinically studied dietary supplement ingredient. Boswellic acids are natural, selective 5-lipoxygenase inhibitors. 3-O-acetyl-11-keto-ß-boswellic acid or “AKBA” is the most active.
Sourced from the forests of India, Boswellia has been used in Ayurvedic medicine for thousands of years.
Boswellia serrata trees are handed down in Indian families as a source of wealth and income.
Rhodiola rosea is a plant native to remote Arctic climates in Asia, Europe and North America.
The root of the plant contains around 140 chemical compounds including phenols, rosavin, rosarin, salidroside and more.
Kale chips cold-pressed put a bird on it mumblecore kogi brooklyn farm-to-table blue bottle yuccie authentic kombucha migas. Literally tilde tacos paleo.
Kale chips cold-pressed put a bird on it mumblecore kogi brooklyn farm-to-table blue bottle yuccie authentic kombucha migas. Literally tilde tacos paleo.
5-LOXIN has been the subject of 13 pre-clinical studies and 2 human clinical trials. One of the key features of 5-LOXIN in any formulation is clinical work that has demonstrated efficacy starting at 7 days – at a significantly lower dose (100 mg) than other joint health ingredients. Efficacy was shown in Visual Analog Score (VAS), Lequesne Functional Index (LFI) and Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain, stiffness and function evaluations.
Beyond joint comfort and flexibility improvements, 5-LOXIN also positively impacts biological markers associated with joint health and inflammation, including TNFa, CRP, and IL-6. It was also shown to significantly inhibit matrix metalloproteinase (MMP-3), enzymes that break down cartilage, collagen and connective tissues.
A 75 subject, 90-day, double-blind, randomized, placebo-controlled study was conducted to evaluate the efficacy and safety of 5-LOXIN in the treatment of osteoarthritis (OA) of the knee. Subjects received either 100 mg (n = 25) or 250 mg (n = 25) of 5-Loxin daily or a placebo. At the end of the study, both doses of 5-Loxin conferred clinically and statistically significant improvements in pain scores and physical function scores in OA patients.
Sengupta K, Alluri KV, Satish AR, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. 2008;10(4):R85. doi:10.1186/ar2461
A 90-day, double-blind, randomized, placebo-controlled study was conducted to evaluate the comparative efficacy and tolerability of 5-Loxin(®) and Aflapin(®) in the treatment of osteoarthritis (OA) of the knee. Sixty OA subjects received either 100 mg (n=20) of 5-Loxin® or 100 mg (n=20) of Aflapin® or a placebo (n=20) daily for 90 days. Each patient was evaluated for pain and physical functions by using the standard tools.
Krishanu Sengupta, et al Int J Med Sci 2010 Nov 1;7(6):366-77. doi: 10.7150/ijms.7.366.
Multiple clinical studies on 5-LOXIN demonstrate efficacy starting at 7 days – with a low dose.
Today’s seniors travel more, play more and do more than ever. 5-LOXIN can help them get moving and keep moving.
Inflammation from exercise has similarities to the type of inflammation that occurs with the aging process.
5-LOXIN can help your customers succeed in achieving their weight management goals by giving them the freedom to workout.
Boswellia serrata, native to India, is one of 19 species of the genus Boswellia. PLT Boswellia-based ingredients are sourced only from select regions of India.
The plant resin of the Boswellia tree provides a commercial oil known as frankincense, which has a “woody, spicy and haunting smell.” It is possibly best known through the biblical story of the Three Wise Men, who delivered gifts of gold, frankincense, and myrrh.
The harvest of Boswellia oleo gum resin occurs through “wounding and healing” of the tree, termed “tapping,” shallow debarking the tree to expose resin glands and stimulate resin production. Harvest is stopped from May through October or November in order to allow a period for tree recovery.
Boswellia serrata oleo gum resin extracts are evaluated for unique characteristic features. Laila Nutraceuticals has developed an identification method using fingerprint profiles and high-performance thin-layer chromatography (HPTLC) and high-performance liquid chromatography (HPLC).
Laila Nutraceuticals facilities maintain third-party Good Manufacturing Practices (GMP) certification from NSF International. The NSF certification includes compliance to the U.S. FDA Food Safety Modernization Act (FSMA) and cGMP 21 CFR 117 + 21 CFR 111.
The starting point for 5-LOXIN – Boswellia serrata – is a plant that produces Indian frankincense. It is also known as Indian olibanum, Salai guggul, and Sallaki in Sanskrit. The plant is native to much of India and the Punjab region that extends into Pakistan. In partnership with Laila, PLT is committed to the safety and fair treatment of the people who harvest 5-LOXIN. We want to support the long-term health and well-being of the tribal culture and the natural environment upon which it relies.
Every batch of the 5-LOXIN harvest is assigned a specific batch number, and each batch of finished product is traced to a specific region and set of trees. 5-LOXIN is tested and must comply with predefined specifications for different parameters at different stages of product manufacturing – from raw materials to finished product. Quality is monitored by a multi-disciplinary organization with dedicated departments for taxonomy (botanical Identification), raw material analysis, chemical analysis, microbiology, and more.
During the fourth quarter of 2021, PLT Health Solutions announced the commencement of a third-party sustainability audit program on Boswellia serrata trees, which serve as the raw material source for some of our most important ingredients. The audit of this India resource was conducted by renowned botanical research consultancy Botanical Liaisons, LLC, and was undertaken to help the nutraceutical industry and non-governmental agencies around the world understand what we and our ingredient innovation partner Laila Nutraceuticals have known for many years: proper stewardship of natural resources and social responsibility toward the communities that support our work are both the right thing to do and good business.
The audit program was a step in PLT’s campaign to document the sustainability of the tree resource. PLT’s Chairman, Paul Flowerman, made field trips to the key production areas in 2018 and 2019 to observe and document the variety of tree populations, methods of natural and forced propagation and the status of the tribal groups involved in the care of the trees and resin production.
A third audit program was based on a broad range of environmental, cultural and economic parameters. In March 2022 Botanical Liaisons reported to PLT its preliminary conclusions, which included this statement: “It is clear from the information collected from the stakeholders that [sustainability] is supported. Boswellia serrata has several sustainability advantages that prevent over-harvesting of PLT-sourced Boswellia compared to other sources and species of Boswellia.” The report recommended a series of next steps to further evaluate and promote sustainability.
Subsequently, four important additional developments have added considerable strength to the Boswellia serrata sustainability story:
These initiatives represent the type of work we do with our PLT360™ initiative. Introduced in 2015, our PLT360 initiative is a business-wide commitment by PLT Health Solutions to develop ingredients that our customers can be confident and proud to supply to their own customers – knowing that these ingredients are safe, of high quality, efficacious and harvested and manufactured sustainably. PLT360 examines every business decision and business process we undertake to be transparent with our operations, build trust with the health & well-being community and, together with them, support healthier, happier lives for the consumers we serve.
At PLT, we are working on the concept of Mobility Solutions - making these solutions available for people of all ages and walks of life. We’re thinking about athletes who want to perform better and recover faster. We’re thinking about people who have physically demanding jobs who don’t want to or can’t take a day off from work. We’re thinking about anyone who has an active lifestyle who wants to embrace it despite the rigors. And yes, we’re thinking about the global aging population.
PLT Health Solutions’ leading portfolio of mobility support ingredients – based on more than a decade of ongoing research – has been developed to help you deliver innovative products that can capture the attention and the trust of consumers. All of our ingredients are backed by multiple clinical studies – and offer rapid improvements from a low dose - in just about any delivery system you can imagine.
Collector in Madhya Pradesh
PLT Health Solutions, Inc is launching a new breakthrough ingredient called Nutricog® Cognitive Performance Complex at Vitafoods Europe on 9 May at Booth G135.
PLT has a broad range of joint health solutions that can work in almost any type of product you’re making.